Study on the Response to Tetanus Vaccination of People Living With HIV

Centre Hospitalier de Niort210 enrolled

Overview

The response to primary tetanus immunization of HIV-infected children is lower than that of uninfected children. Response to tetanus toxoid (TT) booster doses in adults living with HIV who have received primary vaccination prior to infection is not known. Currently, it is recommended to have a TT booster for people living with HIV (PLHIV) every 10 years. In general population, this recall is made only at 25, 45 and 65 years, then every 10 years.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

210

Conditions

HIV Infections

Interventions

additional blood samplingDIAGNOSTIC_TEST

additional blood sampling

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Person aged ≥ 18 years * Person infected with HIV followed in the infectious diseases department of CH Niort * Born in France * Affiliate or beneficiary of a social security scheme * Being able to give free and informed consent to participation in research Exclusion Criteria: * Persons with a contraindication to tetanus vaccination * Persons under guardianship or curatorship or without civil law

Locations (1)

Centre Hospitalier de Niort

Niort, France

Outcomes

Primary Outcomes

the vaccine response to tetanus vaccination

An anti-tetanus IgG level\> 0.1 is considered long-term protective. An anti-tetanus IgG level between 0.01 and 0.1 is considered protective in the short term. The measurement of the vaccine response will be correlated with the age of the last VAT recall (\<10 years, between 10 and 20 years,\> 20 years and unknown)

Time frame: Month 6

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.